France hits Roche and Novartis with €444 million fine
France’s Competition Authority has fined Roche, Novartis and Genentech a total of €444 million for abusing their collective dominance by preventing the entry of a cheaper eye treatment drug into the French market.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10